1. Home
  2. NCRA vs JAGX Comparison

NCRA vs JAGX Comparison

Compare NCRA & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nocera Inc.

NCRA

Nocera Inc.

N/A

Current Price

$1.98

Market Cap

4.7M

ML Signal

N/A

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$2.71

Market Cap

4.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCRA
JAGX
Founded
2002
2013
Country
Taiwan
United States
Employees
20
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
4.9M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
NCRA
JAGX
Price
$1.98
$2.71
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$60.00
AVG Volume (30 Days)
2.5M
463.2K
Earning Date
04-15-2026
04-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
82.42
EPS
N/A
N/A
Revenue
$13,627,944.00
$11,511,000.00
Revenue This Year
N/A
$61.58
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.06
$0.20
52 Week High
$3.98
$8.00

Technical Indicators

Market Signals
Indicator
NCRA
JAGX
Relative Strength Index (RSI) 51.73 82.16
Support Level $1.72 $0.47
Resistance Level $2.59 $3.07
Average True Range (ATR) 0.28 0.20
MACD -0.02 0.24
Stochastic Oscillator 18.23 74.00

Price Performance

Historical Comparison
NCRA
JAGX

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Share on Social Networks: